Advancium will evaluate ALRN-6924 as a potential therapy for retinoblastoma, a rare but devastating pediatric cancer of the eye During the option period, Advancium intends to evaluate ALRN-6924 as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results